Ocuphire Pharma Investor Day Presentation Deck
APX3330 VEGF Effects in Normal Cells
DME APX3330 Restores Normal Levels Unlike Biologic Anti-VEGFs that Reduce VEGF Below Normal
DR
Normal Conditions:
Physiological level
of VEGF activity
Abnormal Conditions
(e.g., hypoxic):
Increased level of
VEGF activity
Biologic anti-VEGF agents inactivate
VEGF directly and reduce VEGF levels
below normal levels.
Biologic
Anti-VEGF
Treatment
APX3330
Anti-Ref-1
Treatment
DM
Inhibition of Ref-1 by APX3330
returns VEGF levels to normal levels.
APX3330 prevents VEGF overproduction in ARPE-19 cells
14 Kamba 2007; Girardi 2010; Li 2014; APX3330 Investigator Brochure
VEGF Concentrations
(% of Control)
500
450
400
350
300
250
200
150
100
50
0
oxLDL
APX3330
ARPE-19 cell line
+
*
p<0.05
+ 150μg/mL
+ 30μM
VEGF is a growth factor that is necessary for normal function of multiple cell types including vascular endothelium and neurons → By returning
VEGF levels to normal, APX3330 can reduce neovascularization, vascular leakage and the inflammatory response without adverse systemic effects
The safety profile of APX3330 to date in over 300 subjects has not shown any of the adverse effects that has been seen with systemic administration
of anti-VEGF biologics such as cardiovascular pathology, hypertension, arteriothrombotic events, or renal dysfunction
Ocuphire
PHARMAView entire presentation